Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

2 results about "T helper cell" patented technology

The T helper cells (Tₕ cells), also known as CD4⁺ cells, are a type of T cell that play an important role in the immune system, particularly in the adaptive immune system. They help the activity of other immune cells by releasing T cell cytokines. These cells help suppress or regulate immune responses. They are essential in B cell antibody class switching, in the activation and growth of cytotoxic T cells, and in maximizing bactericidal activity of phagocytes such as macrophages.

Methods for determining the risk of age-related functional decline

PCT designated stageWO2026082766A1Health-index calculationDisease diagnosisCellular respirationFunctional decline
Aging progresses at different rates among individuals, underscoring the need for better indicators of functional decline. The inventors showed that the T cell energy metabolism in the elderly reveals that high mitochondrial oxidative phosphorylation, especially in CD4 T regulatory cells, is associated with a reduced probability of being frail / prefrail, independent of age, sex, or comorbidities. When mitochondrial respiration drops below a critical threshold, it adversely affects intrinsic capacity. Furthermore, a low level of oxidative phosphorylation in CD4 T helper cells, particularly in central and effector memory subsets, was significantly associated with a faster decline in intrinsic capacity over time, suggesting that T cell mitochondrial bioenergetics represents a key biomarker for managing functional decline in older adults. Accordingly, the present invention relates to a method for determining the risk of age-related functional decline in a subject comprising the step of measuring the mitochondrial dependency in a population of T cells wherein the mitochondrial dependency (MitoDep) correlates with the age-related functional decline.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +2

Fusion-modified virus-like particles of cmv

PendingCN122344261AEpitopeVirus-like particle
The present invention relates to a modified virus-like particle (VLP) of Cucumber Mosaic Virus (CMV) comprising at least one fusion protein, wherein the at least one fusion protein comprises or preferably consists of b) a chimeric CMV polypeptide, wherein the chimeric CMV polypeptide comprises or preferably consists of (iii) a CMV polypeptide, wherein the CMV polypeptide comprises a coat protein of CMV; and (iv) an antigen polypeptide, wherein the antigen polypeptide is inserted into the CMV polypeptide, wherein the insertion of the antigen polypeptide is between amino acid residues corresponding to position 84 and position 85 of SEQ ID NO: 62 of the CMV polypeptide; and (iii) a T helper cell epitope, wherein the T helper cell epitope replaces an N-terminal region of the CMV polypeptide, and wherein preferably the N-terminal region of the CMV polypeptide corresponds to amino acids 2-12 of SEQ ID NO: 62.
Owner:SAIBA AG